FACTORS PREDICTIVE FOR TUMOR CONTROL AMONG HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH SORAFENIB

被引：0
|
作者：
Tortora, R. [1 ]
Lanza, A. Galeota [1 ]
Lampasi, F. [1 ]
De Luca, M. [1 ]
Tartaglione, M. T. [1 ]
Pacilio, R. [1 ]
Di Costanzo, G. G. [1 ]
机构：
[1] Cardarelli Hosp, Liver Unit, Naples, Italy
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)60662-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
660
引用
收藏
页码：S266 / S266
页数：1
相关论文
共 50 条
  • [31] Biological downstaging of intermediate hepatocellular carcinoma in patients treated with sorafenib
    Vitale, A.
    Morales, R. Ramirez
    Cillo, U.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S89 - S89
  • [32] Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib
    Moser, Monika
    Radu, Iuliana-Pompilia
    Dufour, Jean-Francois
    JGH OPEN, 2021, 5 (08): : 864 - 870
  • [33] Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib
    da Costa Ferreira, Caroline Petersen
    Ribeiro, Mauricio Alves
    Szutan, Luiz Arnaldo
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (03): : 275 - 283
  • [34] BIOLOGICAL DOWNSTAGING OF INTERMEDIATE HEPATOCELLULAR CARCINOMA IN PATIENTS TREATED WITH SORAFENIB
    Vitale, Alessandro
    Morales, Rafael Ramirez
    Cillo, Umberto
    HEPATOLOGY, 2010, 52 (04) : 883A - 884A
  • [35] Biomarkers of Apoptosis and Necrosis in Patients with Hepatocellular Carcinoma Treated with Sorafenib
    Godin, Corinne
    Louandre, Christophe
    Bodeau, Sandra
    Diouf, Momar
    Saidak, Zuzana
    Conte, Marie-Alix
    Chauffert, Bruno
    Barbare, Jean-Claude
    Barget, Nathalie
    Trinchet, Jean-Claude
    Ganne, Nathalie
    Galmiche, Antoine
    ANTICANCER RESEARCH, 2015, 35 (03) : 1803 - 1808
  • [36] Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression
    Apostolidis, Leonidas
    Pfeiffenberger, Jan
    Gotthardt, Daniel
    Radeleff, Boris
    Mehrabi, Arianeb
    Schemmer, Peter
    Jaeger, Dirk
    Schirmacher, Peter
    Stremmel, Wolfgang
    Schulze-Bergkamen, Henning
    Springfeld, Christoph
    Weiss, Karl Heinz
    GASTROINTESTINAL TUMORS, 2018, 5 (1-2) : 38 - 46
  • [37] Predictors of time to progression in patients treated with sorafenib for hepatocellular carcinoma
    Salimi, S.
    Mudaliar, S.
    Davison, S.
    Shackel, N.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 92 - 93
  • [38] Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib
    Biselli, Maurizio
    Reggidori, Nicola
    Iavarone, Massimo
    Renzulli, Matteo
    Lani, Lorenzo
    Granito, Alessandro
    Piscaglia, Fabio
    Lorenzini, Stefania
    Alimenti, Eleonora
    Vara, Giulio
    Caraceni, Paolo
    Sangiovanni, Angelo
    Marignani, Massimo
    Gigante, Elia
    Brandi, Nicolo
    Gramenzi, Annagiulia
    Trevisani, Franco
    CANCERS, 2024, 16 (06)
  • [39] LEVOCARNITINE INHIBITS PRESARCOPENIA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB
    Nagai, Hidenari
    Amanuma, Makoto
    Mukozu, Takanori
    Kobayashi, Kojiro
    Watanabe, Go
    Ogino, Yu
    Matsui, Teppei
    Daido, Yasuko
    Wakui, Noritaka
    Momiyama, Koichi
    Igarashi, Yoshinori
    HEPATOLOGY, 2021, 74 : 654A - 655A
  • [40] Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib
    Ozenne, Violaine
    Paradis, Valerie
    Pernot, Simon
    Castelnau, Corinne
    Vullierme, Marie-Pierre
    Bouattour, Mohamed
    Valla, Dominique
    Farges, Olivier
    Degos, Francoise
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (09) : 1106 - 1110
12345